Drugs and FDA
Merck reports remigromig met primary endpoint in diabetic eye disease trial
Both remigromig doses were noninferior to ranibizumab at Week 52, but Merck reported higher rates of several adverse events.
Merck’s phase 2b/3 Brunello trial of remigromig met its primary endpoint in people with diabetic macular edema, Fierce Biotech reported. The trial compared the drug with ranibizumab. Both doses of remigromig were noninferior to ranibizumab at Week 52 on change in best-corrected visual acuity, according to the report.
Merck said remigromig was well tolerated, but reported higher rates of proliferative diabetic retinopathy, vitreous hemorrhage and treatment discontinuations because of adverse events than with ranibizumab. The company is conducting further analyses. BioPharma Dive reported that the full first-year results are expected at a medical meeting on Oct. 10.
